

Beginning mid-2020, pharmaceutical manufacturers started overcharging covered entities (CEs) on 340B drugs shipped to CE contract pharmacies. This chart serves as a summary and timeline of these manufacturer restrictions.

*Updated November 7, 2023*

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<b>Eli Lilly</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies; recent changes allow 340B pricing if CEs submit contract pharmacy claims data. Any covered entity that doesn't have an in-house pharmacy <a href="#">can choose a single location contract pharmacy</a> . <b>UPDATE:</b> Need to submit data to <b>ESP to get 340B pricing at one contract pharmacy</b> . All CE's with or without an in-house patient pharmacy must designate one contract pharmacy location to bill to/ ship Lilly 340B priced drugs. Lilly recognizes all sites as one covered entity. CE's must register one single contract pharmacy designation and voluntary data submission by November 13, 2023, via 340BESP.com	<b>All covered entities (CEs)</b>	September 1, 2020 <b>Updated restriction effective:</b> November 16, 2023
<b>AstraZeneca</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies. <a href="#">May designate a single contract pharmacy</a> but <a href="#">each parent site</a> can have one pharmacy site for itself.	<b>All CEs</b>	October 1, 2020 <b>Updated restriction effective:</b> August 1, 2023

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><u>UPDATE</u>: Moves admin of 340B contract pharmacy program to 340B ESP. Covered entities without an on-site dispensing pharmacy will need to select a single contract pharmacy location using the 340B ESP portal.</p>		
<p><b>Sanofi</b></p>	<p><u>NEW for hospitals</u>: Refusing to ship 340B-priced drugs to contract pharmacies regardless of data submission to 340B ESP. If a CE lacks an in-house, can select 1 contract pharmacy. Doesn't affect CHCs.</p> <p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that doesn't have an in-house pharmacy <u>can choose</u> a single location contract pharmacy. If submitting data to 340B ESP, can choose unlimited contract pharmacies.</p>	<p>5 CE types: Consol, CHC, CAH, DSH, RRC, SCH</p>	<p><b>NEW</b> for hospitals: Effective June 1, 2023 October 1, 2020</p>
<p><b>Novartis</b></p>	<p>Refusing 340B pricing for drugs shipped to contract pharmacies <u>more than 40 miles away from hospitals' parent sites</u></p>	<p>Hospitals only</p>	<p>November 16, 2020</p>
<p><b>Novo Nordisk</b></p>	<p><u>UPDATE</u>: Will not allow hospitals to get 340B-priced drugs to unlimited contract pharmacies even if submitting to 340B ESP</p>	<p>Hospitals only</p>	<p>January 1, 2021 <u>New restrictions effective</u> July 1, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	Previously, allowed hospitals to <b><u>designate two contract pharmacies to receive 340B drugs</u></b> (one specialty, one regular)		
<b>United Therapeutics</b>	Phase 1: Orders for contract pharmacy drugs accepted only if CE made a “valid 340B purchase” during first three quarters of 2020. <b><u>Phase 2:</u></b> Then, refusing 340B pricing for drugs dispensed at all contract pharmacies, unless CE submits claims data.	<b>All CEs</b>	Phase 1: November 20, 2020 Phase 2: December 1, 2021
<b>Boehringer Ingelheim</b>	Will ship 340B drugs only to CEs and their child sites. Any covered entity that does not have an in-house pharmacy <b><u>can choose one contract pharmacy to receive 340B drugs.</u></b> <b><u>UPDATE:</u></b> BI will no longer provide drugs at the 340B price on drug shipments to contract pharmacies. Any CE that doesn’t have an in-house pharmacy can choose one contract pharmacy receive 340B drugs located within 40 miles of the parent site; cannot be a central fill pharmacy. Any CE that doesn’t have an in-house pharmacy capable of dispensing specialty drugs may also designate one (1) specialty pharmacy from within BI’s network to only dispenses OFEV at the 340B price to its patients. CEs must take action by <b>July 14,</b>	<b>Hospitals, CHCs</b>	August 1, 2021 <b>As of September 1, 2022: Includes health centers</b> <b>New restrictions:</b> Effective August 1, 2023

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><b>2023</b>, to either designate or re-designate the single contract pharmacy location.</p>		
<p><b>Merck</b></p>	<p><b><u>NEW:</u></b> Will not allow multiple contract pharmacies to receive discounts even if CE submits data to 340B ESP. If a CE lacks an in-house pharmacy, can select 1 contract pharmacy within 40 miles of its parent site. Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <b><u>can elect one contract pharmacy at a single location.</u></b></p> <p><b><u>Update:</u></b> Effective July 31, 2023 no longer restricts 340B drugs in Louisiana or Arkansas.</p>	<p><b>Hospitals, CHCs</b></p>	<p><b>New restrictions:</b> Effective June 12, 2023</p> <p>September 1, 2021 <b>As of May 31, 2022:</b> <b>Includes health centers</b></p>
<p><b>UCB</b></p>	<p>Will provide 340B priced drugs to locations registered as 340B covered entities or child sites. Any covered entity that does not have an in-house pharmacy <b><u>can elect one contract pharmacy at a single location.</u></b></p> <p><b><u>UPDATE:</u></b> Contract Pharmacies that are owned by a CE or under common ownership by a CE Health system can be designated as a CE’s single contract pharmacy but <b><i>will no longer be</i></b></p>	<p>Hospitals only</p>	<p>December 13, 2021 <b>New restrictions:</b> Effective October 2, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><i>separately eligible to receive 340B pricing.</i> The single contract pharmacy location by CE without in-house pharmacy must be located <b>within 40 miles</b> of the CE parent site. 340B contracts administered by UCB wholesalers will no longer support provision of drugs purchased at the 340B discount price to contract pharmacies under UCB's prior policy after October 2, 2023.</p>		
<p><b>Amgen</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location (single HIN)</a></p> <p><u>Update:</u> Conditions have been placed on 340B sales and deliveries to <b>covered entity in-house pharmacies</b>. A hospital must designate a pharmacy by March 27.</p> <p>If you do not have an in-house pharmacy, you can pick ONE contract pharmacy, AND you must share claims data AND the pharmacy must be within 40 miles of the parent.</p> <p>If you do have an in-house pharmacy, same rules (one</p>	<p>Hospitals only</p>	<p>January 3, 2022  <b>New restrictions:</b>  Effective April 11, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	pharmacy within 40 miles and must share data).		
<b>AbbVie</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location.</a>	Hospitals only	February 1, 2022
<b>Pfizer</b>	Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <a href="#">can elect one contract pharmacy at a single location (single HIN)</a> <a href="#">Update:</a> Adds 15 more medications to the limited contract pharmacy distribution – see the full list <a href="#">here</a> . CEs that do not have an in-house pharmacy can make their single contract pharmacy designation by October 20, 2023, at 340besp.com.	Hospitals only	March 1, 2022 <b>New Restrictions: Effective November 1, 2023</b>
<b>Bristol Myers Squibb</b>	Refusing 340B pricing for “non-IMiD” (Immunomodulatory imide drug) products dispensed at contract pharmacies; modifying access to 340B pricing under IMiD limited distribution network. <a href="#">Will recognize up to 2</a>	Hospitals for non-IMiDs; <b>All CEs for IMiDs</b> <b>Update: All grantees</b>	March 1, 2022 <b>New Restrictions: Effective November 1, 2023</b>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><a href="#">contract pharmacies</a> (one for non-IMiDs, another for IMiDs).  <b>UPDATE:</b> Will recognize up to three contract pharmacies (one for Non-IMiDs, one for IMiDs, and one for Camzyos) for each CE. Only one 340B purchase on a single eligible IMiD prescription allowed.</p>		
<p><b>GlaxoSmithKline</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy may <a href="#">designate one contract pharmacy location (single HIN)</a> to have drugs shipped to. Applies to all drugs (especially impacts inhalers and certain HIV drugs).  <b>UPDATE:</b> Prohibition of unlimited contract pharmacies for all CE's. Claims data is no longer a requirement under <a href="#">GSK's policy</a>. CEs without an in-house outpatient pharmacy must designate one contract pharmacy location. CE's unable to dispense specialty/oncology will restrict 340B pricing on of blood cancer products must designate one specialty pharmacy for each of GSK's limited pharmacy network products.</p>	<p>Hospitals, <b>all grantees</b></p>	<p>April 1, 2022  <b>New restrictions:  Effective May 1, 2023</b></p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><u>Update:</u> Restrictions extend to Ojjaara, a cancer drug.</p> <p><u>UPDATE:</u> Effective November 1, 2023, covered entities in Arkansas and Louisiana will be able to get 340B-priced drugs at contract pharmacies.</p>		
<b>Gilead</b>	<p>Refusing 340B pricing for brand-name Hepatitis C drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <u>may designate a single contract pharmacy location</u>. Likewise, this update does not apply to contract pharmacies that are wholly owned by a covered entity or health system.</p>	All CEs	May 2, 2022
<b>Johnson &amp; Johnson</b>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies; specifically: immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary arterial hypertension, and chemotherapy-induced anemia. If they choose not to submit data, <u>may still designate a single contract pharmacy location (single HIN)</u>. <u>UPDATE:</u> J&amp;J has placed conditions on 340B sales and deliveries to <b>covered entity in-house pharmacies</b>. A hospital</p>	Hospitals only	<p>May 2, 2022</p> <p><b>New restrictions:</b> Effective March 7, 2023</p>



Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p>must designate a pharmacy by February 26; they define outside pharmacy as “a Ship To location that is not part of the Bill To purchaser”; If you do not have an in-house pharmacy, you can pick ONE pharmacy, AND you must share claims data AND the pharmacy must be within 40 miles of the parent. If you do have an in-house pharmacy, same rules (one pharmacy within 40 miles and must share data). Can also select a single specialty pharmacy for specialty drugs.</p>		
<p><b>Exelixis</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies, specifically Cometriq and Cabometyx (cancer drugs). If they choose not to submit data, <u>may still designate a single contract pharmacy location (single HIN)</u>. <b>UPDATE:</b> Extends 340B restrictions to contract pharmacies that are wholly-owned or under common ownership with a covered entity.</p>	<p>Hospitals only; grantees exempt “until further notice”</p>	<p>July 6, 2022 <b>New restrictions:</b> Effective June 26, 2023</p>
<p><b>Bausch</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy <u>can elect</u></p>	<p>All CEs</p>	<p>August 1, 2022 <b>New restrictions:</b> Effective June 26, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p><b>one contract pharmacy at a single location (single HIN).</b>  <b>UPDATE:</b>            Extending its conditions on 340B pricing to contract pharmacies that are wholly owned or under common ownership with a hospital covered entity. Any covered entity that does not have an in-house pharmacy capable of dispensing 340B purchased drugs to its patients may designate a single contract pharmacy location within 40 miles of the covered entity.</p>		
<b>Biogen</b>	<p>Refusing 340B pricing for drugs, specifically Avonex and Plegridy (which treat multiple sclerosis), dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <b><u>designate one contract pharmacy location (single HIN)</u></b> to have drugs shipped to.</p>	Hospitals only	February 1, 2023
<b>Bayer</b>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <b><u>designate one contract pharmacy (single HIN)</u></b> to have drugs shipped to. Drugs excluded</p>	Hospitals only	March 1, 2023 <b>New restrictions:</b> Effective June 1, 2023

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p>from this restriction, for now, include: Adempas, Aliqopa, Jivi, Kerendia, Kogenate, Kovaltry, Kyleena, Lampit, Mirena, Skyla, Nubeqa, Xofigo.</p> <p><b>UPDATE:</b> Hospitals that lack an in-house pharmacy can designate one contract pharmacy location within 40 miles of the hospital parent site. Bayer will no longer let hospitals place replenishment orders for multiple contract pharmacies in exchange for submitting 340B claims to 340B ESP for Bayer drugs. Hospitals may voluntarily provide claims data for their single designated contract pharmacy through 340B ESP.</p>		
<b>EMD Serono</b>	<p>Refusing 340B pricing for drugs, specifically Refib (interferon beta-1a) and Gonal-f (follitropin alfa for injection), dispensed at contract pharmacies if 340B contract pharmacy claims data are not submitted. Any covered entity that does not have an in-house pharmacy can <a href="#">designate one contract pharmacy location (single HIN)</a> to have drugs shipped to.</p> <p><b>UPDATE:</b> Extending its restrictions to ALL medications. If a hospital CE is</p>	Hospitals only	<p>March 1, 2023</p> <p><b>New Restrictions:</b> October 1, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
	<p>granted an exemption for its wholly/commonly owned contract pharmacy(ies), it may <b>not</b> also designate an independent contract pharmacy, except with respect to 340B purchases of <i>Serostim</i>. 340B CEs that do not have an in-house pharmacy and have not already registered an account with 340B ESP™</p> <p><a href="http://www.340besp.com/designations">www.340besp.com/designations</a>.</p>		
<p><b>Organon</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies if 340B contract pharmacy claims aren't submitted. Any covered entity that doesn't have an in-house pharmacy can <b>designate one contract pharmacy location (single HIN)</b> to have drugs shipped to.</p> <p><b>UPDATE:</b> Effective December 1, 2023, covered entities in Arkansas and Louisiana will be able to receive 340B-priced drugs to an unlimited number of contract pharmacies provided claims level data is submitted via 340B ESP for these pharmacies.</p>	<p>Hospitals only</p>	<p>July 1, 2023 Update Effective: December 1, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<p><b>Teva</b></p>	<p>Refusing 340B pricing for drugs dispensed at contract pharmacies. Affected drugs include Copaxone, Ajoyv, and Treanda. Any covered entity that doesn't have an in-house pharmacy can <a href="#">designate one contract pharmacy location (single HIN)</a> within 40 miles of its parent site to have drugs shipped to and must submit claims data. 340B discounted products will only be shipped to the in-house outpatient pharmacy. Designation of new pharmacy must be made by June 18, 2023. <b>UPDATE:</b> Effective September 26, 2023, allows shipment/delivery of 340B drugs to unlimited number of contract pharmacies in <a href="#">Arkansas</a>; ended restrictions in Louisiana as well in July 2023. <b>UPDATE:</b> Effective October 23, 2023, Austedo and Austedo XR product families are now a part of 340B Program Integrity Initiative.</p>	<p>Hospitals only</p>	<p>July 5, 2023  Effective: September 26, 2023  Effective: November 6, 2023</p>

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<b>Astellas</b>	<p>Refusing 340B pricing, specifically for its prostate cancer drug Xtandi, to contract pharmacies. Any covered entity that doesn't have an in-house pharmacy can <a href="#">designate one single contract pharmacy location (single HIN)</a> and must submit claims data. 340B discounted products will only be shipped to the in-house outpatient pharmacy. Designation of new pharmacy must be made by August 18, 2023.</p> <p><a href="#">UPDATE:</a> Effective October 17, 2023, will facilitate orders of Xtandi products at 340B price to an unlimited number of contract pharmacies located within the states of Arkansas and Louisiana.</p>	Hospitals only	September 1, 2023
<b>Jazz Pharmaceuticals</b>	<p>Refusing 340B pricing specifically for <a href="#">Epidiolex</a> products, dispensed at contract pharmacies. CE that has a contact pharmacy either wholly or commonly owned, must use wholly owned pharmacy as the single contract pharmacy or designate one contract pharmacy location by September 29, 2023 at <a href="#">340B ESP</a>.</p>	Hospitals only	September 29, 2023

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<b>Incyte</b>	Refusing 340B pricing for <a href="#">Opzelura</a> dispensed at contract pharmacies. CE without an in-house outpatient pharmacy may designate one contract pharmacy location within 40 miles of CE parent site. CE without an in-house outpatient pharmacy, must designate one contract pharmacy location by October 6, 2023, at <a href="#">340B ESP</a> . If CE can't identify an eligible contract pharmacy, Incyte will work with CE to find a suitable alternative.	Hospitals only	October 16, 2023
<b>Eisai</b>	Refusing 340B pricing for <a href="#">drugs</a> dispensed at contract pharmacies. CE will no longer be able to place orders to bill to/ship to Eisai-covered outpatient drugs for delivery to CPs. CEs without an in-house outpatient pharmacy must designate one contract pharmacy location by October 22, 2023, at <a href="#">340B ESP</a> .	Hospitals only	November 1, 2023

Manufacturer Name	Type of Restriction	Who it Applies to	Effective Date
<b>Sandoz</b>	Covered entity hospitals must designate 1 contract pharmacy location within 40 miles of the CE parent for shipment of <a href="#">listed products at the 340B price</a> . If CE lacks both in-house or wholly owned pharmacy, Sandoz and its vendor will work with CE to identify an appropriate contract pharmacy to dispense covered outpatient drugs. Visit <a href="http://340besp.com">340besp.com</a> to designate a single contract pharmacy before December 1, 2023.	Hospitals only	December 1, 2023